Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

Posted: July 11, 2024 at 2:44 am

SYDNEY, July 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to report promising results from its latest study on the efficacy of RECCE® 327 (R327) against multidrug- resistant (MDR) World Health Organization (WHO) priority pathogen Acinetobacter baumannii (A. baumannii). The study was conducted at Recce’s Anti-Infective Research (AIR) unit within Murdoch Children’s Research Institute.

See more here:
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

Related Posts